Carotuximab
Monoclonal antibody | |
---|---|
Type | ? |
Source | Chimeric (mouse/human) |
Target | endoglin |
Clinical data | |
Other names | TRC-105 |
ATC code |
|
Identifiers | |
CAS Number |
|
ChemSpider |
|
UNII |
|
KEGG |
|
Chemical and physical data | |
Formula | C6420H9922N1718O2010S46 |
Molar mass | 144808.77 g·mol−1 |
Carotuximab (INN[1]) (TRC-105) is a chimeric monoclonal antibody designed for the treatment of cancer.
This drug was developed by Tracon Pharmaceuticals Inc.[2]
It is at Phase III trials for angiosarcoma.
References
- ^ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114" (PDF). WHO Drug Information. 29 (4).
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Carotuximab, American Medical Association.